Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Lowered by Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

MNPR has been the topic of several other reports. Piper Sandler set a $95.00 price objective on Monopar Therapeutics and gave the stock an “overweight” rating in a report on Thursday, September 25th. Oppenheimer set a $115.00 price target on shares of Monopar Therapeutics and gave the stock an “outperform” rating in a research report on Thursday, October 2nd. Barclays set a $125.00 price target on shares of Monopar Therapeutics and gave the company an “overweight” rating in a report on Monday, October 13th. Lake Street Capital began coverage on shares of Monopar Therapeutics in a report on Tuesday, September 23rd. They set a “buy” rating and a $106.00 price objective for the company. Finally, Chardan Capital boosted their target price on shares of Monopar Therapeutics from $85.00 to $100.00 and gave the stock a “buy” rating in a research report on Sunday, November 9th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Monopar Therapeutics has an average rating of “Buy” and a consensus price target of $106.20.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $80.38 on Friday. Monopar Therapeutics has a one year low of $20.61 and a one year high of $105.00. The stock’s 50 day moving average price is $85.31 and its 200 day moving average price is $56.26. The firm has a market capitalization of $536.94 million, a PE ratio of -23.37 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total transaction of $35,000,066.69. Following the sale, the insider owned 272,026 shares in the company, valued at $17,303,573.86. This represents a 66.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP bought a new stake in shares of Monopar Therapeutics in the 3rd quarter worth approximately $18,904,000. Vanguard Group Inc. lifted its stake in Monopar Therapeutics by 140.7% in the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock valued at $17,005,000 after buying an additional 121,729 shares during the last quarter. Deerfield Management Company L.P. bought a new stake in Monopar Therapeutics in the third quarter valued at $13,048,000. TCG Crossover Management LLC acquired a new position in shares of Monopar Therapeutics during the third quarter valued at $12,496,000. Finally, ADAR1 Capital Management LLC grew its position in shares of Monopar Therapeutics by 28.7% during the third quarter. ADAR1 Capital Management LLC now owns 129,999 shares of the company’s stock worth $10,617,000 after acquiring an additional 29,025 shares during the last quarter. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.